Cargando…

Intratumoral Microbiome of Human Primary Liver Cancer

Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome c...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Dingding, Wang, Yi, Xia, Qingxin, Chang, Jing, Jiang, Xiangnan, Zhang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234634/
https://www.ncbi.nlm.nih.gov/pubmed/35191218
http://dx.doi.org/10.1002/hep4.1908
_version_ 1784736123080146944
author Qu, Dingding
Wang, Yi
Xia, Qingxin
Chang, Jing
Jiang, Xiangnan
Zhang, He
author_facet Qu, Dingding
Wang, Yi
Xia, Qingxin
Chang, Jing
Jiang, Xiangnan
Zhang, He
author_sort Qu, Dingding
collection PubMed
description Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome can directly or indirectly impact cancer initiation, progression, and response to therapy, including cancer immunotherapy; however, the roles of the microbiota in the tumor microenvironment are not clear and require more investigation. Here, we investigated intratumoral microbial community profiling on formalin‐fixed paraffin‐embedded tissue samples of patients with PLC by 16S ribosomal RNA using the MiSeq platform. We characterized the microbial communities in different histopathological subtypes and in the different prognoses of patients with PLC. The study revealed microbial population differences not only in carcinoma tissue and the matched adjacent nontumor tissue but in different histopathological subtypes, even in patients with PLC with different prognoses. Interestingly, the abundance of certain bacteria that have antitumor effects at family and genus level, such as Pseudomonadaceae, decreased in tumor tissue and was linearly associated with prognosis of patients with PLC. Conclusion: We provide a potential novel diagnostic biomarker and therapeutic strategy for early clinical diagnosis and treatment of PLC.
format Online
Article
Text
id pubmed-9234634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92346342022-06-30 Intratumoral Microbiome of Human Primary Liver Cancer Qu, Dingding Wang, Yi Xia, Qingxin Chang, Jing Jiang, Xiangnan Zhang, He Hepatol Commun Original Articles Primary liver tumors (PLCs) and liver metastasis currently represent the leading cause of cancer‐related deaths worldwide due to poor outcomes, high incidence, and postsurgical recurrence. Hence, novel diagnostic markers and therapeutic strategies for PLCs are urgently needed. The human microbiome can directly or indirectly impact cancer initiation, progression, and response to therapy, including cancer immunotherapy; however, the roles of the microbiota in the tumor microenvironment are not clear and require more investigation. Here, we investigated intratumoral microbial community profiling on formalin‐fixed paraffin‐embedded tissue samples of patients with PLC by 16S ribosomal RNA using the MiSeq platform. We characterized the microbial communities in different histopathological subtypes and in the different prognoses of patients with PLC. The study revealed microbial population differences not only in carcinoma tissue and the matched adjacent nontumor tissue but in different histopathological subtypes, even in patients with PLC with different prognoses. Interestingly, the abundance of certain bacteria that have antitumor effects at family and genus level, such as Pseudomonadaceae, decreased in tumor tissue and was linearly associated with prognosis of patients with PLC. Conclusion: We provide a potential novel diagnostic biomarker and therapeutic strategy for early clinical diagnosis and treatment of PLC. John Wiley and Sons Inc. 2022-02-22 /pmc/articles/PMC9234634/ /pubmed/35191218 http://dx.doi.org/10.1002/hep4.1908 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Qu, Dingding
Wang, Yi
Xia, Qingxin
Chang, Jing
Jiang, Xiangnan
Zhang, He
Intratumoral Microbiome of Human Primary Liver Cancer
title Intratumoral Microbiome of Human Primary Liver Cancer
title_full Intratumoral Microbiome of Human Primary Liver Cancer
title_fullStr Intratumoral Microbiome of Human Primary Liver Cancer
title_full_unstemmed Intratumoral Microbiome of Human Primary Liver Cancer
title_short Intratumoral Microbiome of Human Primary Liver Cancer
title_sort intratumoral microbiome of human primary liver cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234634/
https://www.ncbi.nlm.nih.gov/pubmed/35191218
http://dx.doi.org/10.1002/hep4.1908
work_keys_str_mv AT qudingding intratumoralmicrobiomeofhumanprimarylivercancer
AT wangyi intratumoralmicrobiomeofhumanprimarylivercancer
AT xiaqingxin intratumoralmicrobiomeofhumanprimarylivercancer
AT changjing intratumoralmicrobiomeofhumanprimarylivercancer
AT jiangxiangnan intratumoralmicrobiomeofhumanprimarylivercancer
AT zhanghe intratumoralmicrobiomeofhumanprimarylivercancer